Pharming Group (NASDAQ:PHAR) Shares Gap Up to $7.27

Pharming Group (NASDAQ:PHAR)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $7.27, but opened at $8.00. Pharming Group shares last traded at $8.40, with a volume of 2,031 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Friday, May 31st.

Pharming Group Stock Up 10.0 %

The company has a 50 day simple moving average of $9.21 and a 200-day simple moving average of $10.76. The stock has a market cap of $538.72 million, a price-to-earnings ratio of -52.50 and a beta of 0.18.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.20). Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. The firm had revenue of $55.59 million for the quarter, compared to the consensus estimate of $68.43 million. On average, equities research analysts expect that Pharming Group will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.